Document is current
Any future updates will be listed below
-
Authors
Djinbachian, Roupen
von Renteln, Daniel
- License Information
-
More Information
Article History
Accepted: 12 November 2021
First Online: 24 March 2022
Declarations
:
: Roupen Djinbachian declares that he has no conflict of interest. Daniel von Renteln is supported by the “Fonds de Recherche du Québec Santé” career development award and has received research funding from ERBE, Ventage, Pendopharm, and Pentax and is a consultant for Boston Scientific and Pendopharm.
